CY2011A - Film-coated solid dosage form of anti-migraine drug - Google Patents

Film-coated solid dosage form of anti-migraine drug Download PDF

Info

Publication number
CY2011A
CY2011A CY201198A CY201198A CY2011A CY 2011 A CY2011 A CY 2011A CY 201198 A CY201198 A CY 201198A CY 201198 A CY201198 A CY 201198A CY 2011 A CY2011 A CY 2011A
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
film
solid dosage
active ingredient
dosage form
Prior art date
Application number
CY201198A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CY2011A publication Critical patent/CY2011A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Waveguide Aerials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Non-Reversible Transmitting Devices (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
CY201198A 1991-03-08 1998-02-20 Film-coated solid dosage form of anti-migraine drug CY2011A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919104890A GB9104890D0 (en) 1991-03-08 1991-03-08 Compositions

Publications (1)

Publication Number Publication Date
CY2011A true CY2011A (en) 1998-02-20

Family

ID=42342461

Family Applications (1)

Application Number Title Priority Date Filing Date
CY201198A CY2011A (en) 1991-03-08 1998-02-20 Film-coated solid dosage form of anti-migraine drug

Country Status (29)

Country Link
US (4) US5863559A (nl)
EP (1) EP0503440B1 (nl)
JP (1) JP2986546B2 (nl)
KR (1) KR100202042B1 (nl)
AT (1) ATE165973T1 (nl)
AU (1) AU663303B2 (nl)
BE (1) BE1005086A5 (nl)
CA (1) CA2105180C (nl)
CH (1) CH684242A5 (nl)
CY (1) CY2011A (nl)
CZ (1) CZ282352B6 (nl)
DE (1) DE69225421T2 (nl)
DK (1) DK0503440T3 (nl)
ES (1) ES2117015T3 (nl)
FR (1) FR2673538B1 (nl)
GB (2) GB9104890D0 (nl)
GE (1) GEP20012549B (nl)
HK (1) HK19395A (nl)
IE (1) IE920726A1 (nl)
IL (1) IL101162A (nl)
IT (1) IT1271495B (nl)
MX (1) MX9200992A (nl)
NL (1) NL9200423A (nl)
NZ (1) NZ241873A (nl)
OA (1) OA09812A (nl)
RU (1) RU2098093C1 (nl)
SG (1) SG169294G (nl)
WO (1) WO1992015295A1 (nl)
ZA (1) ZA921690B (nl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
DE4314976C1 (de) * 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
GB9924717D0 (en) * 1999-10-19 1999-12-22 Glaxo Group Ltd Diagnostic
AT500063A1 (de) 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
RU2005104827A (ru) * 2002-07-19 2006-07-27 Рэнбакси Лабораториз Лимитед (In) Таблетки суматриптана с замаскированным вкусом и способы их получения
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2609185A1 (en) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2008049116A2 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)
AU2009260166B2 (en) * 2008-06-20 2014-10-09 Alphapharm Pty Ltd Pharmaceutical formulation
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
CA2729346A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
NZ599344A (en) 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
BR112017018944A2 (en) 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79215B (nl) * 1982-06-07 1984-10-22 Glaxo Group Ltd
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions

Also Published As

Publication number Publication date
NL9200423A (nl) 1992-10-01
ITRM920155A0 (it) 1992-03-06
GB2254784B (en) 1994-11-16
WO1992015295A1 (en) 1992-09-17
OA09812A (en) 1994-04-15
US5863559A (en) 1999-01-26
IL101162A (en) 1997-11-20
JP2986546B2 (ja) 1999-12-06
ITRM920155A1 (it) 1993-09-06
JPH06505020A (ja) 1994-06-09
ATE165973T1 (de) 1998-05-15
BE1005086A5 (fr) 1993-04-13
CA2105180A1 (en) 1992-09-09
IL101162A0 (en) 1992-11-15
CA2105180C (en) 1999-08-17
GEP20012549B (en) 2001-10-25
HK19395A (en) 1995-02-17
FR2673538B1 (fr) 1995-05-12
GB9204761D0 (en) 1992-04-15
DK0503440T3 (da) 1999-01-18
RU2098093C1 (ru) 1997-12-10
DE69225421T2 (de) 1998-10-15
ZA921690B (en) 1993-08-02
CH684242A5 (fr) 1994-08-15
CZ184993A3 (en) 1994-06-15
GB2254784A (en) 1992-10-21
IT1271495B (it) 1997-05-30
CZ282352B6 (cs) 1997-07-16
AU1326492A (en) 1992-10-06
GB9104890D0 (en) 1991-04-24
EP0503440A1 (en) 1992-09-16
US6368627B1 (en) 2002-04-09
US6020001A (en) 2000-02-01
EP0503440B1 (en) 1998-05-13
NZ241873A (en) 1994-06-27
MX9200992A (es) 1992-09-01
DE69225421D1 (de) 1998-06-18
AU663303B2 (en) 1995-10-05
KR100202042B1 (ko) 1999-06-15
SG169294G (en) 1995-04-28
US20020197318A1 (en) 2002-12-26
FR2673538A1 (fr) 1992-09-11
ES2117015T3 (es) 1998-08-01
IE920726A1 (en) 1992-09-09

Similar Documents

Publication Publication Date Title
CA2105180C (en) Compositions containing sumatriptan
US6515010B1 (en) Carvedilol methanesulfonate
KR100202154B1 (ko) 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제
KR100421347B1 (ko) 약학 혼합 제제
JPH07165584A (ja) 二重層オキカルバゼピン錠剤
EP1450770B1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
MXPA97006053A (en) Compressed trimebutin maleate with lami coating
WO2004096182A1 (en) Extended release matrix tablets of carvedilol
US20060193915A1 (en) Compression coated tablets
MXPA01005300A (es) Preparaciones de combinacion farmaceutica
HK1069111B (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
WO2008075321A2 (en) Modified-release formulations of azabicyclo derivatives